169 related articles for article (PubMed ID: 37958791)
21. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation.
Dragon AC; Zimmermann K; Nerreter T; Sandfort D; Lahrberg J; Klöß S; Kloth C; Mangare C; Bonifacius A; Tischer-Zimmermann S; Blasczyk R; Maecker-Kolhoff B; Uchanska-Ziegler B; Abken H; Schambach A; Hudecek M; Eiz-Vesper B
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33127653
[TBL] [Abstract][Full Text] [Related]
22. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
23. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
[TBL] [Abstract][Full Text] [Related]
24. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
25. Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo MF; Welters C; Rosenberger L; Leisegang M; Dietze K; Pircher C; Penter L; Gary R; Bullinger L; Takvorian A; Moosmann A; Dornmair K; Blankenstein T; Kammertöns T; Gerbitz A; Hansmann L
Cytotherapy; 2022 Aug; 24(8):818-826. PubMed ID: 35525797
[TBL] [Abstract][Full Text] [Related]
26. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Lin FY; Stuckert A; Tat C; White M; Ruggieri L; Zhang H; Mehta B; Lapteva N; Mei Z; Major A; Thakkar S; Shum T; Parikh K; Wu MF; Lindsay HB; Scherer L; Shekar M; Baxter P; Wang T; Grilley B; Moeller K; Hicks J; Roy A; Anastas J; Malbari F; Aldave G; Chintagumpala M; Blaney S; Parsons DW; Brenner MK; Heslop HE; Rooney CM; Omer B
J Clin Oncol; 2024 May; ():JCO2302019. PubMed ID: 38771986
[TBL] [Abstract][Full Text] [Related]
27. Identification of IgH gene rearrangement and immunophenotype in an animal model of Epstein-Barr virus-associated lymphomas.
Zhang Y; Peng X; Tang Y; Gan X; Wang C; Xie L; Xie X; Gan R; Wu Y
J Med Virol; 2016 Oct; 88(10):1804-13. PubMed ID: 26991077
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus (EBV) provides survival factors to EBV
Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
[TBL] [Abstract][Full Text] [Related]
29. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
[TBL] [Abstract][Full Text] [Related]
30. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
Fogg MH; Wirth LJ; Posner M; Wang F
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
[TBL] [Abstract][Full Text] [Related]
31. EBV-induced T-cell responses in EBV-specific and nonspecific cancers.
Zhang Q; Xu M
Front Immunol; 2023; 14():1250946. PubMed ID: 37841280
[TBL] [Abstract][Full Text] [Related]
32. Redirecting T Cells against Epstein-Barr Virus Infection and Associated Oncogenesis.
Münz C
Cells; 2020 Jun; 9(6):. PubMed ID: 32512847
[TBL] [Abstract][Full Text] [Related]
33. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
34. Non-viral
Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
[TBL] [Abstract][Full Text] [Related]
35. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
36. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
[TBL] [Abstract][Full Text] [Related]
37. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Front Immunol; 2023; 14():878953. PubMed ID: 37033971
[TBL] [Abstract][Full Text] [Related]
38. High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments.
Nakhoul H; Lin Z; Wang X; Roberts C; Dong Y; Flemington E
mSphere; 2019 Jul; 4(4):. PubMed ID: 31292228
[TBL] [Abstract][Full Text] [Related]
39. Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.
Shatzer A; Ali MA; Chavez M; Dowdell K; Lee MJ; Tomita Y; El-Hariry I; Trepel JB; Proia DA; Cohen JI
Leuk Lymphoma; 2017 Apr; 58(4):923-931. PubMed ID: 27686857
[TBL] [Abstract][Full Text] [Related]
40. [Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].
He HZ; Xing YY; Zhang Y; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):229-234. PubMed ID: 35405781
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
